Interleukin-5 (IL-5) is the principal cytokine regulating eosinophil growth, differentiation, activation, and expression. It is a specific target of mepolizumab, an anti-IL-5 monoclonal antibody used in the treatment of severe eosinophilic asthma. This new drug can improve symptoms, reduce asthma exacerbations and steroid use. Few data are available on its efficacy for nasal symptoms.
Cameli, P., Bergantini, L., D'Alessandro, M., Perruzza, M., Cekorja, B., Perillo, F., et al. (2020). A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 181(8), 606-612 [10.1159/000507996].
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting
Cameli, Paolo;Bergantini, Laura;d'Alessandro, Miriana;Perillo, Felice;Bargagli, Elena
2020-01-01
Abstract
Interleukin-5 (IL-5) is the principal cytokine regulating eosinophil growth, differentiation, activation, and expression. It is a specific target of mepolizumab, an anti-IL-5 monoclonal antibody used in the treatment of severe eosinophilic asthma. This new drug can improve symptoms, reduce asthma exacerbations and steroid use. Few data are available on its efficacy for nasal symptoms.
| File | Dimensione | Formato | |
|---|---|---|---|
|
mepo real-life comprehensive.pdf
non disponibili
Descrizione: Articolo
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
284.98 kB
Formato
Adobe PDF
|
284.98 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1111166